Revance Therapeutics Inc

NASDAQ:RVNC   3:59:43 PM EDT
24.16
+0.14 (+0.58%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.46B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$5.6 Million
Adjusted EPS-$1.18
See more estimates
10-Day MA$24.48
50-Day MA$25.70
200-Day MA$23.02
See more pivots

Revance Therapeutics, Inc. Stock, NASDAQ:RVNC

7555 GATEWAY BLVD., NEWARK, CA 94560
United States of America
Phone: 510-742-3400
Number of Employees: 170

Description

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.